Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.

被引：11
|
作者：
Higano, Celestia S.
Sternberg, Cora N.
Saad, Fred
Tombal, Bertrand F.
Miller, Kurt
Kalinovsky, Jan
Jiao, XiaoLong
Tangirala, Krishna
Sartor, A. Oliver
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[3] Weill Cornell Med, Englander Inst Precis Med, New York, NY USA
[4] Univ Montreal, Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[5] Clin Univ St Luc, Brussels, Belgium
[6] Charite, Dept Urol, Berlin, Germany
[7] Bayer Healthcare Pharmaceut Inc, Basel, Switzerland
[8] Bayer Healthcare Pharmaceut Inc, Whippany, NJ USA
[9] Tulane Med Sch, New Orleans, LA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.256
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
256
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and tumors with androgen receptor (AR) 878/875 mutations
    Stewart, T. F.
    Gedrich, R.
    Saha, J.
    Chirnomas, D.
    Edwards, M.
    Lang, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1188 - S1188
  • [42] Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    George, Daniel J.
    Sternberg, Cora N.
    Sartor, A. Oliver
    Saad, Fred
    Tombal, Bertrand F.
    Miller, Kurt
    Kalinovsky, Jan
    Jiao, XiaoLong
    Tangirala, Krishna
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [43] Real world outcomes with cabazitaxel (cab) plus carboplatin (car) in metastatic castration-resistant prostate cancer (mCRPC)
    Vemuru, Shalini
    Goyal, Subir
    Liu, Yuan
    Zhuang, Tony
    Patel, Deven
    Kucuk, Omer
    Carthon, Bradley Curtis
    Nazha, Bassel
    Bilen, Mehmet Asim
    Brown, Jacqueline T.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] Prevalence and management of castration-resistant prostate cancer of unknown metastatic status in the real-world setting: The AfroDiTA study
    Rodrigo-Aliaga, Miguel
    Alvarez-Ossoriob, Jose L.
    Rodriguez-Alonsoc, Andres
    Garcia-Porrerod, Angela
    Quesada-Garciad, Alba
    del Torod, Jacobo Munoz
    Rodriguez-Antolin, Alfredo
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (01) : 64e11 - 64e18
  • [45] Prevalence of castration-resistant prostate cancer (CRPC) of unknown metastatic status in the real-world setting: The AfrODiTA study
    Rodrigo-Aliaga, M.
    Alvarez-Ossorio, J. L.
    Rodriguez-Alonso, A.
    Garcia Garcia-Porrero, A.
    Quesada-Garcia, A.
    Munoz del Toro, J.
    Rodriguez-Antolin, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S646 - S646
  • [46] The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population
    Westgeest, H. M.
    Kuppen, M. C. P.
    van den Eertwegh, A. J. M.
    de Wit, R.
    Bergman, A. M.
    van Moorselaar, R. J. A.
    Coenen, J. L. L. M.
    van den Bergh, A. C. M.
    Somford, D. M.
    Mehra, N.
    van Oort, I. M.
    Aben, K. K. H.
    Gerritsen, W. R.
    Uyl-de Groot, C. A.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (03) : 871 - 879
  • [47] The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population
    H. M. Westgeest
    M. C. P. Kuppen
    A. J. M. van den Eertwegh
    R. de Wit
    A. M. Bergman
    R. J. A. van Moorselaar
    J. L. L. M. Coenen
    A. C. M. van den Bergh
    D. M. Somford
    N. Mehra
    I. M. van Oort
    K. K. H. Aben
    W. R. Gerritsen
    C. A. Uyl-de Groot
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 871 - 879
  • [48] Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Gebrael, Georges
    Jo, Yeonjung
    Hage Chehade, Chadi
    Ozay, Zeynep Irem
    Sayegh, Nicolas
    Ostrowski, Micah
    Campbell, Patrick
    Anderson, Ethan
    Nordblad, Blake
    Galarza Fortuna, Gliceida M.
    Mathew Thomas, Vinay
    Riaz, Irbaz Bin
    Graf, Ryon P.
    Guha, Avirup
    Maughan, Benjamin L.
    Roy, Soumyajit
    Antonarakis, Emmanuel S.
    Agarwal, Neeraj
    Swami, Umang
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [49] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [50] Real-world analysis of prostate-specific antigen (PSA) outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA)
    Freedland, Stephen J.
    Schultz, Neil M.
    Coutinho, Anna D.
    Fuldeore, Rupali
    Hedlund, Nancy
    Feng, Qi
    Ramaswamy, Krishnan
    Hong, Agnes
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345